Table_3_TCR Repertoire Analysis Reveals Mobilization of Novel CD8+ T Cell Clones Into the Cancer-Immunity Cycle Following Anti-CD4 Antibody Administration.xlsx
Depletion of CD4+ cells using an anti-CD4 monoclonal antibody (anti-CD4 mAb) induces the expansion of tumor-reactive CD8+ T cells and strong antitumor effects in several murine tumor models. However, it is not known whether the anti-CD4 mAb treatment activates a particular or a broad spectrum of tumor-reactive CD8+ T cell clones. To investigate the changes in the TCR repertoire induced by the anti-CD4 mAb treatment, we performed unbiased high-throughput TCR sequencing in a B16F10 mouse subcutaneous melanoma model. By Inter-Organ Clone Tracking analysis, we demonstrated that anti-CD4 mAb treatment increased the diversity and combined frequency of CD8+ T cell clones that overlapped among the tumor, draining lymph node (dLN), and peripheral blood repertoires. Interestingly, the anti-CD4 mAb treatment-induced expansion of overlapping clones occurred mainly in the dLN rather than in the tumor. Overall, the Inter-Organ Clone Tracking analysis revealed that anti-CD4 mAb treatment enhances the mobilization of a wide variety of tumor-reactive CD8+ T cell clones into the Cancer-Immunity Cycle and thus induces a robust antitumor immune response in mice.
History
References
- https://doi.org//10.1200/JCO.2017.74.3062
- https://doi.org//10.1056/NEJMoa1412082
- https://doi.org//10.1056/NEJMoa1510665
- https://doi.org//10.1158/0008-5472.CAN-07-1056
- https://doi.org//10.1084/jem.20041684
- https://doi.org//10.1158/0008-5472.CAN-04-3344
- https://doi.org//10.1158/2326-6066.CIR-14-0190
- https://doi.org//10.1007/s10565-018-9426-0
- https://doi.org//10.1007/s00281-016-0614-9
- https://doi.org//10.1158/1078-0432.CCR-13-2648
- https://doi.org//10.1371/journal.pmed.1002309
- https://doi.org//10.1126/scitranslmed.3008211
- https://doi.org//10.1073/pnas.1611421113
- https://doi.org//10.1016/j.cell.2017.09.028
- https://doi.org//10.1126/scitranslmed.aah3560
- https://doi.org//10.1016/j.immuni.2013.07.012
- https://doi.org//10.1038/nprot.2014.005
- https://doi.org//10.1038/nmeth.3364
- https://doi.org//10.14806/ej.17.1.200
- https://doi.org//10.1093/bioinformatics/btr026
- https://doi.org//10.1371/journal.pcbi.1004503
- https://doi.org//10.1084/jem.20030590
- https://doi.org//10.1158/2326-6066.CIR-17-0489
- https://doi.org//10.1158/2326-6066.CIR-16-0107
- https://doi.org//10.1080/2162402X.2016.1240859
- https://doi.org//10.1016/j.cell.2017.05.035
- https://doi.org//10.1158/2326-6066.CIR-16-0001
- https://doi.org//10.3389/fimmu.2017.01500
- https://doi.org//10.1158/2326-6066.CIR-17-0114
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity